Virtual Challenging Case Clinic: Multiple Myeloma

  • Engage with leading experts to strategize on therapeutic options for your patients
  • Stay up to date on novel agents approved for the treatment of multiple myeloma, and assess recommended sequencing of therapy

Course Director

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Agenda

  • Welcome, Introductions, and Pre-session Survey
  • General Disease State and Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions, and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

AUGUST 18, 2021

Agents Targeting BCMA

Noopur Raje, MD
Dana-Farber Cancer Institute | Boston, Massachusetts

OCTOBER 20, 2021

Aligning Induction Therapy for Each Patient

Saad Usmani, MD, FACP
Atrium Health | Charlotte, North Carolina

DECEMBER 15, 2021

Updates from ASH

Krina Patel, MD, MSc
MD Anderson Cancer Center | Houston, Texas

FEBRUARY 16, 2022

MM-associated AL Amyloidosis

Shaji Kumar, MD
Mayo Clinic | Rochester, Minnesota

This activity is supported by independent educational grants from Bristol-Myers Squibb and Oncopeptides 

Recordings From Previous Webinars: 2021 Series

JUNE 16, 2021

Updates from ASCO and EHA

Jonathan Kaufman, MD
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast: June 16, 2021

CAR T Cells for MM

Nina Shah, MD
UCSF | San Francisco, California
Broadcast on April 21, 2021

This activity is supported by independent educational grants from Bristol-Myers Squibb and Oncopeptides

Recordings From Previous Webinars: 2020 Series

Updates from ASH and Year in Review

Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on January 20, 2021

Emerging Therapeutic Options: What’s On the Horizon?

Adam Cohen, MD
University of Pennsylvania | Philadelphia, Pennsylvania
Broadcast on November 18, 2020

Treating Relapsed/Refractory MM: Sequencing of Therapies

Paul G. Richardson, MD
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on September 16, 2020

Updates from ASCO and EHA

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas
Broadcast on July 15, 2020

Maintenance Therapy Approaches

Nina Shah, MD
University of California, San Francisco | San Francisco, California
Broadcast on May 20, 2020

This activity is supported by independent educational grants from Bristol-Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides

Target Audience

The target audience for this activity is clinicians who treat patients with multiple myeloma: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.

Learning Objectives
  • Evaluate best available evidence regarding the treatment of patients with multiple myeloma
  • Assess the implications of emerging clinical trial data regarding multiple myeloma treatment approaches
  • Develop strategies to address complicated multiple myeloma cases
Continuing Education

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  
Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.